Scilex Holding (SCLX) Common Equity (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Common Equity of -$254.1 million for Q1 2026, down 20.14% year-over-year from -$318.1 million in Q1 2025, and down 19.98% on a QoQ basis from -$211.8 million in Q4 2025.
Scilex Holding (SCLX) Common Equity (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Common Equity for 7 consecutive years, with -$254.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 20.14% year-over-year to -$254.1 million; the TTM figure through Mar 2026 stood at -$254.1 million (down 20.14% YoY), while the FY2025 annual figure was -$211.8 million, down 9.92% from the prior year.
- Common Equity came in at -$254.1 million for Q1 2026 at Scilex Holding, down from -$211.8 million in the prior quarter.
- The five-year high for Common Equity was $36.2 million in Q4 2022, with the low at -$254.1 million in Q1 2026.
- Average Common Equity over 5 years is -$170.7 million, with a median of -$211.3 million recorded in 2024.
- The largest YoY upside for Common Equity was 116.19% in 2022 against a maximum downside of 2906.36% in 2022.
- Year by year, Common Equity stood at $36.2 million in 2022, then plunged by 577.22% to -$172.9 million in 2023, then slipped by 11.39% to -$192.6 million in 2024, then fell by 9.92% to -$211.8 million in 2025, then retreated by 19.98% to -$254.1 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered -$254.1 million, -$211.8 million, and -$176.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 31.20 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 81.19 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -6.61 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 47.38 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 45.93 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 9.19 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 23.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 90.40 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -254.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -254.07 Mn |
| Dec 31, 2025 | -211.75 Mn |
| Sep 30, 2025 | -176.94 Mn |
| Jun 30, 2025 | -248.99 Mn |
| Mar 31, 2025 | -211.48 Mn |
| Dec 31, 2024 | -192.64 Mn |
| Sep 30, 2024 | -211.32 Mn |
| Jun 30, 2024 | -214.69 Mn |
| Mar 31, 2024 | -189.79 Mn |
| Dec 31, 2023 | -172.94 Mn |
| Sep 30, 2023 | -162.67 Mn |
| Jun 30, 2023 | 10.42 Mn |
| Mar 31, 2023 | 11.08 Mn |
| Dec 31, 2022 | 36.24 Mn |
| Sep 30, 2022 | -229.40 Mn |
| Jun 30, 2022 | -252.10 Mn |
| Mar 31, 2022 | -231.57 Mn |
| Dec 31, 2021 | -223.88 Mn |
| Sep 30, 2021 | -9.83 Mn |
| Jun 30, 2021 | -8.39 Mn |